The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

1.2K views · 17 reactions | Every person’s breast cancer experience is different, but there’s one thing that could help anyone facing a diagnosis: answers. Over the past 20 years, the Oncotype DX® test has empowered breast cancer patients to make more informed, personalized treatment decisions. #20YearsofOncotypeDX #BreastCancerAwarenessMonth | Exact Sciences | Facebook

The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows | Facebook